Oliver Surriga

Sustained Inhibition of Receptor Tyrosine Kinases and Macrophage Depletion by PLX3397 and Rapamycin as a Potential New Approach for the Treatment of MPNSTs

Parag P. Patwardhan, Oliver Surriga, Michael J. Beckman et al. · Clinical Cancer Research · 2014 · 118 citations · Full text

Crizotinib, a c-Met Inhibitor, Prevents Metastasis in a Metastatic Uveal Melanoma Model

Oliver Surriga, Vinagolu K. Rajasekhar, Grazia Ambrosini et al. · Molecular Cancer Therapeutics · 2013 · 117 citations · Full text

C-met Inhibitor, Skin Cancer, Medicine +15

Identification of Unique MEK-Dependent Genes in GNAQ Mutant Uveal Melanoma Involved in Cell Growth, Tumor Cell Invasion, and MEK Resistance

Grazia Ambrosini, Christine A. Pratilas, Li-Xuan Qin et al. · Clinical Cancer Research · 2012 · 107 citations · Full text

A Biparatopic Antibody–Drug Conjugate to Treat MET-Expressing Cancers, Including Those that Are Unresponsive to MET Pathway Blockade

John O. DaSilva, Katie Yang, Oliver Surriga et al. · Molecular Cancer Therapeutics · 2021 · 40 citations · Full text

Adjuvant crizotinib in high-risk uveal melanoma following definitive therapy

Shaheer Khan, Jose Lutzky, Alexander N. Shoushtari et al. · Frontiers in Oncology · 2022 · 22 citations · Full text